Loading...
XNASNLSPW
Market cap5mUSD
Jan 10, Last price  
0.02USD
1D
-6.36%
1Q
19.12%
IPO
-97.81%
Name

NLS Pharmaceutics AG

Chart & Performance

D1W1MN
XNAS:NLSPW chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.51%
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L-26.21%
-6,657,127-5,146,766-5,447,145-2,861,435-11,946,078-16,495,680-12,172,029
CFO
-10m
L-30.22%
-5,432,453-2,732,804-190,009-729,386-14,936,044-13,879,371-9,684,466

Profile

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
URL
https://nlspharma.com/
IPO date
Jan 29, 2021
Employees
6
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
11,818
15,476
Unusual Expense (Income)
NOPBT
(11,818)
(15,476)
NOPBT Margin
Operating Taxes
2
Tax Rate
NOPAT
(11,818)
(15,476)
Net income
(12,172)
-26.21%
(16,496)
38.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,101
BB yield
-1.78%
Debt
Debt current
1,634
Long-term debt
Deferred revenue
2,500
2,500
Other long-term liabilities
261
136
Net debt
736
(8,948)
Cash flow
Cash from operating activities
(9,684)
(13,879)
CAPEX
Cash from investing activities
Cash from financing activities
1,634
17,397
FCF
(7,344)
(2,512,114)
Balance
Cash
898
8,948
Long term investments
Excess cash
898
8,948
Stockholders' equity
(69,798)
(57,584)
Invested Capital
65,359
63,501
ROIC
1.29%
ROCE
266.23%
EV
Common stock shares outstanding
38,176
19,683
Price
23.60
-54.27%
51.60
16.22%
Market cap
900,801
-11.31%
1,015,624
55.10%
EV
901,537
1,006,676
EBITDA
(11,807)
(15,464)
EV/EBITDA
Interest
145
101
Interest/NOPBT